Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization
Antibody drug conjugate (ADC) therapy has become one of the most promising approaches in cancer immunotherapy. The bispecific targeting could improve the specificity, affinity, and internalization of the ADC molecules. Prolactin preceptor (PRLR) and HER2 have crosstalk signaling in breast cancer, an...
Saved in:
Main Authors: | Hui-Fang Zong (Author), Bao-Hong Zhang (Author), Jian-Wei Zhu (Author) |
---|---|
Format: | Book |
Published: |
Georg Thieme Verlag KG,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
by: Alexander Rau, et al.
Published: (2021) -
Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024) -
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021) -
The eIg technology to generate Ig-like bispecific antibodies
by: Lennart Kühl, et al.
Published: (2022) -
Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
by: Chia-Hsien Shih, et al.
Published: (2024)